相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Pranavi Koppula et al.
PROTEIN & CELL (2021)
Broadening horizons: the role of ferroptosis in cancer
Xin Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Targeting MCL-1 in cancer: current status and perspectives
Haolan Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Unsaturated fatty acids as a co-therapeutic agents in cancer treatment
Zahra Asefy et al.
MOLECULAR BIOLOGY REPORTS (2021)
Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma
Carmen Oi Ning Leung et al.
HEPATOLOGY (2020)
Cell Death in the Origin and Treatment of Cancer
Andreas Strasser et al.
MOLECULAR CELL (2020)
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo et al.
GUT (2020)
Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin
Li Zong et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy
Viacheslav V. Senichkin et al.
TRENDS IN CELL BIOLOGY (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Recent developments on the extraction and application of ursolic acid. A review
Lucia Lopez-Hortas et al.
FOOD RESEARCH INTERNATIONAL (2018)
Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy
Man Yu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
Cun Wang et al.
JOURNAL OF HEPATOLOGY (2018)
Omega-3 fatty acids, membrane remodeling and cancer prevention
Natividad R. Fuentes et al.
MOLECULAR ASPECTS OF MEDICINE (2018)
Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
Rui Wang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation
Guixian Wu et al.
CELL DEATH & DISEASE (2018)
The role of cellular reactive oxygen species in cancer chemotherapy
Haotian Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Ursolic acid, a potential anticancer compound for breast cancer therapy
Ran Yin et al.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2018)
Characteristics, Biological Properties and Analytical Methods of Ursolic Acid: A Review
Andressa Maria Pironi et al.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY (2018)
Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016)
Hidayat Hussain et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20
Yehuda Patt et al.
ONCOLOGIST (2017)
Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcing autophagy-mediated differentiation
Ting Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Brent R. Stockwell et al.
CELL (2017)
Significance of long chain polyunsaturated fatty acids in human health
Rafael Zarate et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study
Michael Bitzer et al.
JOURNAL OF HEPATOLOGY (2016)
Ursolic acid (UA): A metabolite with promising therapeutic potential
Dharambir Kashyap et al.
LIFE SCIENCES (2016)
Ferrootosis: Death by Lipid Peroxidation
Wan Seok Yang et al.
TRENDS IN CELL BIOLOGY (2016)
Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway
Shouhai Wu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer
Jianzhen Shan et al.
PROTEIN & CELL (2016)
Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species
Haiqing Wang et al.
CELL AND BIOSCIENCE (2015)
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
Yelena Y. Janjigian et al.
PLOS ONE (2015)
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21(CIP1/WAF1) in human cancer cells
Jingru Li et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
DECADE IN REVIEW-HEPATOCELLULAR CARCINOMA HCC-subtypes, stratification and sorafenib
Gregory J. Gores
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies
Muthu K. Shanmugam et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
J. Wan et al.
BRITISH JOURNAL OF CANCER (2013)
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
Angela Gauthier et al.
HEPATOLOGY RESEARCH (2013)
Sensitization of ionizing radiation-induced apoptosis by ursolic acid
Su Jin Koh et al.
FREE RADICAL RESEARCH (2012)
Autophagy-related Gene 7 (ATG7) and Reactive Oxygen Species/Extracellular Signal-regulated Kinase Regulate Tetrandrine-induced Autophagy in Human Hepatocellular Carcinoma
Ke Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S. Steinbild et al.
BRITISH JOURNAL OF CANCER (2007)
ROS stress in cancer cells and therapeutic implications
H Pelicano et al.
DRUG RESISTANCE UPDATES (2004)
分享论文
